The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III non-small cell lung cancer.
Target population is unresectable stage III non-small cell lung cancer.
Written informed consent provided.
Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.
Male and female patients aged ≥18 years, < 75 years.
Known severe hypersensitivity to IBI308 or any of the excipients of this product.
Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
Prior chemotherapy or radiotherapy.
Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.